SilverCloud Health vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
Digital mental health platform delivering evidence-based CBT programs, Dublin Ireland, acquired by Amwell, serves 500+ health systems and payers globally.
About
SilverCloud Health is a Dublin, Ireland-based digital mental health platform founded in 2012 at Trinity College Dublin. The company specializes in delivering structured, evidence-based cognitive behavioral therapy (CBT) programs through an asynchronous digital format supported by a trained human reviewer. SilverCloud was acquired by Amwell in 2021, integrating its digital mental health programs into Amwell's broader virtual care platform serving health systems, health plans, and employers.\n\nThe platform offers more than 20 condition-specific programs covering depression, anxiety, insomnia, chronic pain, diabetes, and workplace stress, among others. Each program is built on clinically validated CBT frameworks and follows a structured curriculum over six to eight weeks. Users work through modules independently and receive feedback and encouragement from a trained human supporter, a model known as supported self-management that has shown strong outcomes in peer-reviewed research.\n\nSilverCloud serves more than 500 health systems, insurers, and employers across the United Kingdom, Ireland, and the United States. Its clinical credibility is underpinned by a robust evidence base of over 90 published research studies, making it one of the most rigorously evaluated digital mental health interventions available. Following the Amwell acquisition, SilverCloud has expanded its reach through Amwell's existing hospital and health plan relationships.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.